Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2017;17:530–6. https://doi.org/10.7861/clinmedicine.17-6-530.
Giovannoni G, Tomic D, Bright JR, et al. “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23:1179–87. https://doi.org/10.1177/1352458517703193.
Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the ‘treatment era’. Nat Rev Neurol. 2015;11:280–9. https://doi.org/10.1038/nrneurol.2015.53.
Shekelle PG, Woolf SH, Eccles M, et al. Developing clinical guidelines. West J Med. 1999;170:348–51.
Portaccio E, Ghezzi A, Hakiki B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85:845–50. https://doi.org/10.1136/jnnp-2013-306054.
Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler. 2014;20:739–46. https://doi.org/10.1177/1352458513507816.
Amato MP, Bertolotto A, Brunelli R, et al. Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurol Sci. 2017;38:1849–58. https://doi.org/10.1007/s10072-017-3081-8.
Langer-Gould A, Huang S, Van Den Eeden SK, et al. Vitamin D, pregnancy, breastfeeding and postpartum multiple sclerosis relapses. Arch Neurol. 2011;68:310–3. https://doi.org/10.1001/archneurol.2010.291.
Runia TF, Neuteboom RF, de Groot CJ, et al. The influence of vitamin D on postpartum relapse and quality of life in pregnant multiple sclerosis patients. Eur J Neurol. 2015;22:479–84. https://doi.org/10.1111/ene.12594.
Roth DE, Leung M, Mesfin E, et al. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. BMJ. 2017;359:j5237. https://doi.org/10.1136/bmj.j5237.
Leader S, Perales PJ. Provision of primary-preventive health care services by obstetrician-gynecologists. Obstet Gynecol. 1995;85:391–5.
Swamy GK, Heine RP. Vaccinations for pregnant women. Obstet Gynecol. 2015;125:212–26. https://doi.org/10.1097/AOG.0000000000000581.
Frederiksen JL, Topsøe Mailand M. Vaccines and multiple sclerosis. Acta Neurol Scand. 2017;136:49–51. https://doi.org/10.1111/ane.12837.
Pellegrino P, Carnovale C, Perrone V, et al. Efficacy of vaccination against influenza in patients with multiple sclerosis: the role of concomitant therapies. Vaccine. 2014;32:4730–5. https://doi.org/10.1016/j.vaccine.2014.06.068.
Keller-Stanislawski B, Englund JA, Kang G, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine. 2014;32:7057–64. https://doi.org/10.1016/j.vaccine.2014.09.052.
Wiley K, Regan A, McIntyre P. Immunization and pregnancy—who, what, when and why? Aust Prescr. 2017;40:122–4. https://doi.org/10.18773/austprescr.2017.046.
Al-Shammri S, Rawoot P, Azizieh F, et al. Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis. J Neurol Sci. 2004;222:21–7.
Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8:223–46.
Gold SM, Voskuhl RR. Estrogen treatment in multiple sclerosis. J Neurol Sci. 2009;286:99–103. https://doi.org/10.1016/j.jns.2009.05.028.
Alroughani R, Alowayesh MS, Ahmed SF, et al. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology. 2018;90:e840–6. https://doi.org/10.1212/WNL.0000000000005065.
Miller DH, Fazekas F, Montalban X, et al. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler. 2014;20:527–36. https://doi.org/10.1177/1352458513519840.
Smets I, Van Deun L, Bohyn C, et al. Corticosteroids in the management of acute multiple sclerosis exacerbations. Acta Neurol Belg. 2017;117:623–33. https://doi.org/10.1007/s13760-017-0772-0.
Xiao WL, Liu XY, Liu YS, et al. The relationship between maternal corticosteroid use and orofacial clefts—a meta-analysis. Reprod Toxicol. 2017;69:99–105. https://doi.org/10.1016/j.reprotox.2017.02.006.
Vackova Z, Vagnerova K, Libra A, et al. Dexamethasone and betamethasone administration during pregnancy affects expression and function of 11 beta-hydroxysteroid dehydrogenase type 2 in the rat placenta. Reprod Toxicol. 2009;28:46–51. https://doi.org/10.1016/j.reprotox.2009.02.006.
Hellwig K, Beste C, Schimrigk S, et al. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord. 2009;2:7–11. https://doi.org/10.1177/1756285608100416.
Finkelsztejn A, Fragoso YD, Ferreira ML, et al. The Brazilian database on pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2011;113:277–80. https://doi.org/10.1016/j.clineuro.2010.11.016.
Fares J, Nassar AH, Gebeily S, et al. Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study. BMJ Open. 2016;6:e011210. https://doi.org/10.1136/bmjopen-2016-011210.
Jesus-Ribeiro J, Correia I, Martins AI, et al. Pregnancy in multiple sclerosis: a Portuguese cohort study. Mult Scler Relat Disord. 2017;17:63–8. https://doi.org/10.1016/j.msard.2017.07.002.
Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2013;115:154–9. https://doi.org/10.1016/j.clineuro.2012.04.024.
Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009;66:958–63. https://doi.org/10.1001/archneurol.2009.132.
Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology. 2011;77:145–50. https://doi.org/10.1212/WNL.0b013e318224afc9.
Pakpoor J, Disanto G, Lacey MV, et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol. 2012;259:2246–8. https://doi.org/10.1007/s00415-012-6553-z.
Holla-Bhar R, Iellamo A, Gupta A, Smith JP, Dadhich JP. Investing in breastfeeding—the world breastfeeding costing initiative. Int Breastfeed J. 2015;10:18. https://doi.org/10.1186/s13006-015-0032-y.
Rosa GR, O’Brien AT, Nogueira EA, et al. There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis. Arq Neuropsiquiatr. 2018;76:361–6. https://doi.org/10.1590/0004-282x20180041.
de Seze J, Chapelotte M, Delalande S, et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler. 2004;10:596–7.
Boz C, Terzi M, Zengin Karahan S, et al. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. Mult Scler. 2017. https://doi.org/10.1177/1352458517717806.
Cooper SD, Felkins K, Baker TE, et al. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31:237–9. https://doi.org/10.1177/0890334415570970.
Hellwig K. Pregnancy in multiple sclerosis. Eur Neurol. 2014;72:39–42. https://doi.org/10.1159/000367640.
Masera S, Cavalla P, Prosperini L, et al. Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Mult Scler. 2015;21:1291–7. https://doi.org/10.1177/1352458514561907.
McCombe PA, Callaway LK. Multiparity in women with multiple sclerosis causes less long-term disability: no. Mult Scler. 2014;20:1435–6. https://doi.org/10.1177/1352458514541979.
Dahl J, Myhr KM, Daltveit AK, et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005;65:1961–3.
Chen YH, Lin HL, Lin HC. Does multiple sclerosis increase risk of adverse pregnancy outcomes? A population-based study. Mult Scler. 2009;15:606–12. https://doi.org/10.1177/1352458508101937.
Mueller BA, Zhang J, Critchlow CW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol. 2002;186:446–52.
Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2004;115:3–9.
Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79:1130–5. https://doi.org/10.1212/WNL.0b013e3182698c64.
Bornemann-Cimenti H, Sivro N, Toft F, et al. Neuraxial anesthesia in patients with multiple sclerosis—a systematic review. Rev Bras Anestesiol. 2017;67:404–10. https://doi.org/10.1016/j.bjan.2016.09.015.
Pastò L, Portaccio E, Ghezzi A, et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol. 2012;12:165. https://doi.org/10.1186/1471-2377-12-165.
Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015;17(350):h1798. https://doi.org/10.1136/bmj.h1798.
Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry. 2013;35(3):265–71. https://doi.org/10.1016/j.genhosppsych.2012.12.010.
Yonkers KA, Forray A, Smith MV. Maternal antidepressant use and pregnancy outcomes. JAMA. 2017;318(7):665–6. https://doi.org/10.1001/jama.2017.9182.
Berard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017;7(1):e013372. https://doi.org/10.1136/bmjopen-2016-013372.
Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70(4):436–43. https://doi.org/10.1001/jamapsychiatry.2013.684.
Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51. https://doi.org/10.1001/jama.2015.5605.
Udechuku A, Nguyen T, Hill R, et al. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010;44(11):978–96. https://doi.org/10.3109/00048674.2010.507543.
Grzeskowiak LE, Leggett C, Costi L, et al. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. Br J Clin Pharmacol. 2018;84(6):1373–9. https://doi.org/10.1111/bcp.13575.
Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacol. 2015;30:4–20. https://doi.org/10.1002/hup.2451.
Generali JA, Cada DJ. Amantadine: multiple sclerosis-related fatigue. Hosp Pharm. 2014;49:710–2. https://doi.org/10.1310/hpj4908-710.
Pucci E, Branãs P, D’Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD002818. https://doi.org/10.1002/14651858.CD002818.
Kranick SM, Mowry EM, Colcher A, et al. Movement disorders and pregnancy: a review of the literature. Mov Disord. 2010;25:665–71. https://doi.org/10.1002/mds.23071.
Seier M, Hiller A. Parkinson’s disease and pregnancy: an updated review. Parkinsonism Relat Disord. 2017;40:11–7. https://doi.org/10.1016/j.parkreldis.2017.05.007.
Pandit PB, Chitayat D, Jefferies AL, et al. Tibial hemimelia and tetralogy of Fallot associated with first trimester exposure to amantadine. Reprod Toxicol. 1994;8:89–92.
Shangyan H, Kuiqing L, Yumin X, et al. Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. Mult Scler Relat Disord. 2018;19:85–9. https://doi.org/10.1016/j.msard.2017.10.011.
Ford-Johnson L, DeLuca J, Zhang J, et al. Cognitive effects of modafinil in patients with multiple sclerosis: a clinical trial. Rehabil Psychol. 2016;61:82–91. https://doi.org/10.1037/a0039919.
Maillart E, Gout O, Lubetzki C, et al. Favorable outcome of a pregnancy after fampridine exposition during the first month. J Neurol Sci. 2016;370:158. https://doi.org/10.1016/j.jns.2016.09.033.
Tandon SS, Hoskins I, Azhar S. Intrathecal baclofen pump—a viable therapeutic option in pregnancy. Obstet Med. 2010;3:119–20. https://doi.org/10.1258/om.2010.100016.
Baclofen and pregnancy: birth defects and withdrawal symptoms. Prescrire Int. 2015;24:214.
Safarinejad MR. Evaluation of endocrine profile, hypothalamic–pituitary–testis axis and semen quality in multiple sclerosis. J Neuroendocrinol. 2008;20:1368–75.
Pakpoor J, Goldacre R, Schmierer K, et al. Testicular hypofunction and multiple sclerosis risk: a record-linkage study. Ann Neurol. 2014;76:625–8.
Glazer CH, Tottenborg SS, Giwereman A, et al. Male fator infertility and risk of multiple sclerosis: a register-based cohort study. Mult Scler. 2017. https://doi.org/10.1177/1352458517734069.
Bove R, Musallam A, Healy BC, et al. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014;20:1584–92. https://doi.org/10.1177/1352458514527864.
Brubaker WD, Li S, Baker LC, et al. Increased risk of autoimmune disorders in infertile men: analysis of US claims data. Andrology. 2018;6:94–8.
Prévinaire JG, Lecourt G, Soler JM, et al. Sexual disorders in men with multiple sclerosis: evaluation and management. Ann Phys Rehabil Med. 2014;57:329–36. https://doi.org/10.1016/j.rehab.2014.05.002.
Fode M, Krogh-Jespersen S, Brackett NI, et al. Male sexual dysfunction and infertility associated with neurological disorders. Asian J Androl. 2012;14:61–8.
Marck CH, Jelinek PL, Weiland TJ, et al. Sexual function in multiple sclerosis and associations with demographic, disease and lifestyle characteristics: an international cross-sectional study. BMC Neurol. 2016;16:210.
Balsamo R, Arcaniolo D, Stizzo M, et al. Increased risk of erectile dysfunction in men with multiple sclerosis: an Italian cross-sectional study. Cent Eur J Urol. 2017;70:289–95. https://doi.org/10.1155/2017/9820245.
Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010;257:580–3. https://doi.org/10.1007/s00415-009-5376-z.
Pecori C, Giannini M, Portaccio E, et al. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol. 2014;14:114. https://doi.org/10.1186/1471-2377-14-114.
Lu E, Zhu F, Zhao Y, et al. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. CNS Drugs. 2014;28:475–82. https://doi.org/10.1007/s40263-014-0154-6.
Trofimenko V, Hotaling JM. Fertility treatment in spinal cord injury and other neurologic disease. Transl Androl Urol. 2016;5:102–16. https://doi.org/10.3978/j.issn.2223-4683.2015.12.10.
Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol. 2013;149:219–24. https://doi.org/10.1016/j.clim.2013.02.001.
Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750. https://doi.org/10.1002/14651858.cd001750.pub4.
Niino M, Hirotani M, Fukazawa T, et al. Estrogens as potential therapeutic agents in multiple sclerosis. Cent Nerv Syst Agents Med Chem. 2009;9:87–94.
Vaughn C, Bushra A, Kolb C, et al. An update on the use of disease-modifying therapy in pregnant patients with multiple sclerosis. CNS Drugs. 2018;32:161–78. https://doi.org/10.1007/s40263-018-0496-6.
Krueger WS, Anthony MS, Saltus CW, et al. Evaluating the safety of medication exposures during pregnancy: a case study of study designs and data sources in multiple sclerosis. Drugs Real World Outcomes. 2017;4:139–49. https://doi.org/10.1007/s40801-017-0114-9.
Fragoso YD. Is it correct for a woman with multiple sclerosis to forgo medication because she may become pregnant? Arq Neuropsiquiatr. 2013;71:826–7. https://doi.org/10.1590/0004-282X20130134.
Meinl I, Havla J, Hohlfeld R, et al. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. Mult Scler. 2017. https://doi.org/10.1177/1352458517731913.
Novi G, Ghezzi A, Pizzorno M, et al. Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. Neurol Neuroimmunol Neuroinflamm. 2017;4:e377. https://doi.org/10.1212/NXI.0000000000000377.
De Giglio L, Gasperini C, Tortorella C, et al. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand. 2015;131:336–40. https://doi.org/10.1111/ane.12364.
Martinelli V, Colombo B, Dalla Costa G, et al. Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult Scler. 2016;22:1506–8.
Verhaeghe A, Deryck OM, Vanopdenbosch LJ. Pseudotumoral rebound of multiple sclerosis in a pregnant patient after stopping natalizumab. Mult Scler Relat Disord. 2014;3:279–81. https://doi.org/10.1016/j.msard.2013.10.001.
Sempere AP, Berenguer-Ruiz L, Feliu-Rey E. Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur J Neurol. 2013;20:e109–10. https://doi.org/10.1111/ene.12195.
Saposnik G, Montalban X. Therapeutic inertia in the new landscape of multiple sclerosis care. Front Neurol. 2018;9:174. https://doi.org/10.3389/fneur.2018.00174.
Markowitz C. Development of interferon-beta as a therapy for multiple sclerosis. Expert Opin Emerg Drugs. 2004;9:363–74.
Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007;68:S8–11.
Waysbort A, Giroux M, Mansat V, et al. Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrob Agents Chemother. 1993;37:1232–7.
Madsen C. The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis. Brain Behav. 2017;7:e00696. https://doi.org/10.1002/brb3.696.
Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009;14:363–80. https://doi.org/10.1517/14728210902907847.
Hu X, Olivier K, Polack E, et al. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a. J Pharmacol Exp Ther. 2011;338:984–96. https://doi.org/10.1124/jpet.111.180661.
Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005;65:802–6.
Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005;65:807–11.
Patti F, Cavallaro T, Lo Fermo S, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol. 2008;255:1250–3. https://doi.org/10.1007/s00415-008-0909-4.
Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17:423–30. https://doi.org/10.1177/1352458510394610.
Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology. 2010;75:1794–802. https://doi.org/10.1212/WNL.0b013e3181fd62bb.
Coyle PK, Sinclair SM, Scheuerle AE, et al. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4:e004536. https://doi.org/10.1136/bmjopen-2013-004536.
Thiel S, Langer-Gould A, Rockhoff M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016;22:801–9. https://doi.org/10.1177/1352458516634872.
Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15:1037–42. https://doi.org/10.1177/1352458509106543.
Organization WH. International statistical classification of diseases and related health problems, tenth revision. 2nd ed. Geneva: World Health Organization; 2004.
Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med. 2012;7:123–5. https://doi.org/10.1089/bfm.2011.0044.
Polman C, Barkhof F, Kappos L, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler. 2003;9:342–8.
Messina S, Patti F. The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. Expert Opin Drug Metab Toxicol. 2013;9:1349–59. https://doi.org/10.1517/17425255.2013.811489.
Comi G, Moiola L. Glatiramer acetate. Neurologia. 2002;17:244–58.
Fragoso YD. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Expert Opin Drug Saf. 2014;13:1743–8. https://doi.org/10.1517/14740338.2014.955849.
Sandberg-Wollheim M, Neudorfer O, Grinspan A, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018;20:9–14. https://doi.org/10.7224/1537-2073.2016-079.
Miller AE. Multiple sclerosis disease-modifying therapy and pregnancy. Mult Scler. 2016;22:715–6. https://doi.org/10.1177/1352458516642316.
Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 2001;24:979–90.
Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91–101. https://doi.org/10.1097/WNF.0b013e3181cbf825.
Buraga I, Popovici RE. Multiple sclerosis and pregnancy: current considerations. Sci World J. 2014;2014:513160. https://doi.org/10.1155/2014/513160.
Orlowski RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma. 2004;45:187–8.
Cronin M, Schellschmidt I, Dinger J. Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives. Obstet Gynecol. 2009;114:616–22. https://doi.org/10.1097/AOG.0b013e3181b46f54.
Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother. 2007;41(10):1660–8.
Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2018;32:269–87. https://doi.org/10.1007/s40263-018-0488-6.
Lu E, Wang BW, Alwan S, et al. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs. 2014;28:89–94. https://doi.org/10.1007/s40263-013-0131-5.
Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674–80. https://doi.org/10.1212/WNL.0000000000000137.
Jones B. Multiple sclerosis: study reinforces need for contraception in women taking fingolimod. Nat Rev Neurol. 2014;10:125. https://doi.org/10.1038/nrneurol.2014.22.
Alroughani R, Altintas A, Al Jumah M, et al. MS pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks. Mult Scler Int. 2016;2016:1034912. https://doi.org/10.1155/2016/1034912.
Yoshii F, Moriya Y, Ohnuki T, et al. Neurological safety of fingolimod: an updated review. Clin Exp Neuroimmunol. 2017;8:233–43. https://doi.org/10.1111/cen3.12397.
Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis. 2016;7:198–207. https://doi.org/10.1177/2040622316653307.
Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994;30:977–81.
Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol. 2018;23:5. https://doi.org/10.3389/fneur.2018.00005.
Blewett MM, Xie J, Zaro BW, et al. Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci Signal. 2016;9:rs10. https://doi.org/10.1126/scisignal.aaf7694.
Gillard GO, Collette B, Anderson J, et al. DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. J Neuroimmunol. 2015;283:74–85. https://doi.org/10.1016/j.jneuroim.2015.04.006.
Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4:93–104. https://doi.org/10.1007/s40120-015-0033-1.
Sheikh SI, Nestorov I, Russell H, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013;35(1582–1594):e9. https://doi.org/10.1016/j.clinthera.2013.08.009.
Fragoso YD, Brooks JB. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol. 2015;8:315–20. https://doi.org/10.1586/17512433.2015.119343.
Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19:835–43. https://doi.org/10.1177/1352458512471880.
Fukushima R, Kanamori S, Hirashiba M, et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor leflunomide in mice. Reprod Toxicol. 2007;24:310–6.
Fukushima R, Kanamori S, Hirashiba M, et al. Critical periods for the teratogenicity of immune-suppressant leflunomide in mice. Congenit Anom (Kyoto). 2009;49:20–6. https://doi.org/10.1111/j.1741-4520.2008.00217.x.
Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014;3(2):133–8.
Bérard A, Zhao JP, Shui I, et al. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis. 2018;77:500–9. https://doi.org/10.1136/annrheumdis-2017-212078.
Weber-Schoendorfer C, Beck E, Tissen-Diabaté T, et al. Leflunomide—a human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol. 2017;71:101–7. https://doi.org/10.1016/j.reprotox.2017.04.007.
Robertson D, Dixon C, Aungst A, et al. Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide. Expert Rev Clin Pharmacol. 2017;10:1403–7. https://doi.org/10.1080/17512433.2017.1395280.
Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther Adv Chronic Dis. 2013;4:192–205. https://doi.org/10.1177/2040622313492810.
Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34:28–35. https://doi.org/10.1097/WNF.0b013e318204cd90.
Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin. 2007;23:2667–76. https://doi.org/10.1185/030079907X233142.
Savic RM, Novakovic AM, Ekblom M, et al. Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet. 2017;56:1245–53. https://doi.org/10.1007/s40262-017-0516-6.
Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, et al. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand. 2010;122:409–13. https://doi.org/10.1111/j.1600-0404.2010.01330.x.
Hartung H, Aktas O, Kieseier B, et al. Development of oral cladribine for the treatment of multiple sclerosis. J Neurol. 2010;257:163–70.
Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360. https://doi.org/10.1212/NXI.0000000000000360.
Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6:821–6. https://doi.org/10.1586/eci.10.77.
Saji F, Samejima Y, Kamiura S, et al. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999;4:81–9.
Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86:328–44. https://doi.org/10.1002/bdrb.20201.
DeSesso JM, Williams AL, Ahuja A, et al. The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit Rev Toxicol. 2012;42:185–210. https://doi.org/10.3109/10408444.2011.653487.
Hao L, Fang-Hong S, Shi-Ying H, et al. A review on clinical pharmacokinetics, pharmacodynamics, and pharmacogenomics of natalizumab: a humanized anti-alpha4 integrin monoclonal antibody. Curr Drug Metab. 2018. https://doi.org/10.2174/1389200219666180427165841 (E-pub).
Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4:571–80.
Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist. 2007;13:182–7.
Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:885–9. https://doi.org/10.1136/jnnp-2015-312940.
Friend S, Richman S, Bloomgren G, et al. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16:150. https://doi.org/10.1186/s12883-016-0674-4.
Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler J. 2011;17:958–63.
Ebrahimi N, Hebstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler J. 2015;21:198–205.
Portaccio E, Annovazzi P, Ghezzi A, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. I: fetal risks. Neurology. 2018. https://doi.org/10.1212/WNL.0000000000005067.
Portaccio E, Annovazzi P, Ghezzi A, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. II: maternal risks. Neurology. 2018. https://doi.org/10.1212/WNL.0000000000005068.
Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891–5.
Guilloton L, Pegat A, Defrance J, et al. Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy. J Gynecol Obstet Hum Reprod. 2017;46:301–2. https://doi.org/10.1016/j.jogoh.2017.02.008.
Schneider H, Weber CE, Hellwig K, et al. Natalizumab treatment during pregnancy—effects on the neonatal immune system. Acta Neurol Scand. 2013;127:e1–4. https://doi.org/10.1111/ane.12004.
Kleerekooper I, Leurs CE, Dekker I, et al. Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e424. https://doi.org/10.1212/NXI.0000000000000424.
Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012;71:604–17. https://doi.org/10.1097/NEN.0b013e31825caf2c.
Proschmann U, Thomas K, Thiel S, et al. Natalizumab during pregnancy and lactation. Mult Scler J. 2017. https://doi.org/10.1177/1352458517728813.
Baker TE, Cooper SD, Kessler L, et al. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31:233–6.
Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62:873–82.
Hale G, Swirsky D, Waldmann H, et al. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol. 1985;60:41–8.
Domagała A, Kurpisz M. CD52 antigen—a review. Med Sci Monit. 2001;7:325–31.
Brown JW, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2013;7:131–8. https://doi.org/10.2147/DDDT.S32687.
Moreau T, Coles A, Wing M, et al. CAMPATH-IH in multiple sclerosis. Mult Scler. 1996;1:357–65.
Oh J, Achiron A, Chambers C, et al. Pregnancy outcomes in patients with RRMS who received alemtuzumab in the clinical development program. Neurology. 2016;86(S24):008.
Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 2007;64:278–91.
Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012;12:335–41. https://doi.org/10.1586/ern.12.5.
Mahzari M, Arnaout A, Freedman MS. Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management. Can J Neurol Sci. 2015;42:284–91. https://doi.org/10.1017/cjn.2015.48.
He D, Guo R, Zhang F, et al. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2013;12:CD009130. https://doi.org/10.1002/14651858.cd009130.pub3.
Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88. https://doi.org/10.1056/NEJMoa0706383.
Frau J, Coghe G, Lorefice L, et al. New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. Neuropsychiatr Dis Treat. 2018;14:1093–9. https://doi.org/10.2147/NDT.S147874.
Vukusic S. An update on pregnancy outcomes following ocrelizumab treatment in patients with multiple sclerosis and other autoimmune diseases. Poster session presented at: ECTRIMS, 2017 Oct 25–28, Paris.
Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499–506. https://doi.org/10.1182/blood-2010-07-295444.
Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5:e453. https://doi.org/10.1212/NXI.0000000000000453.
Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5:826–37. https://doi.org/10.4161/mabs.26008.
Stahnke AM, Holt KM. Ocrelizumab: a new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis. Ann Pharmacother. 2018;52:473–83. https://doi.org/10.1177/1060028017747635.
Mandal PK, Dolai TK, Bagchi B, et al. B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen. Indian J Pediatr. 2014;81(10):1092–4. https://doi.org/10.1007/s12098-013-1336-9.
Vaidyanathan A, McKeever K, Anand B, et al. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci. 2011;119:116–25. https://doi.org/10.1093/toxsci/kfq316.